Table 3.
Univariate logistic regression model for predictors for antibody response after second vaccination (patients only).
| Variable | Patients with antibody responsea (n = 6) |
Patients without antibody responsea (n = 11) |
Odds ratio (95% confidence interval) |
p Value |
|---|---|---|---|---|
| Age in years, median (IQR) | 27 (25–38.5) | 43 (26–55) | 0.96 (0.88–1.03) | 0.250 |
| BMI, median (IQR) | 23.3 (19.4–31.5) | 27.8 (24–31.5) | 0.94 (0.76–1.09) | 0.417 |
| Female gender | 4 (66.7%) | 2 (18.2%) | 6.84 (0.94–67.18) | 0.058 |
| AML | 5 (83.3%) | 7 (63.3%) | 2.20 (0.29–26.79) | 0.459 |
| Myeloablative conditioning regimen | 4 (66.7%) | 4 (36.4%) | 3.00 (0.45–24.16) | 0.257 |
| Related donor | 5 (83.3%) | 4 (36.4%) | 6.11 (0.83–75.72) | 0.077 |
| Prior acute GvHD | 1 (16.7%) | 3 (27.3%) | 0.66 (0.05–5.49) | 0.709 |
| Chronic GvHD | 4 (66.7%) | 8 (72.7%) | 0.74 (0.10–5.94) | 0.768 |
| Any immunosuppressive medication | 4 (66.7%) | 7 (63.6%) | 1.08 (0.16–8.42) | 0.938 |
| EBMT score >2 | 3 (50%) | 8 (72.7%) | 0.41 (0.05–2.86) | 0.366 |
| T cell count/µl, median (IQR) | 1220 (1144–1513) | 766 (576–1115) | 1.00 (1.00–1.00) | 0.196 |
| T cell reconstitutionb | 5 (83.3%) | 3 (27.3%) | 8.90 (1.18–115.07) | 0.033 |
| CD4+ cell count/µl, median (IQR) | 456 (380–544) | 315 (257–387) | 1.01 (1.00–1.03) | 0.019 |
| CD4+CD45RO+ cells in %, median (IQR) | 52.9 (47.2–71) | 64.5 (45.6–73.7) | 0.99 (0.94–1.05) | 0.755 |
| CD4+CD45RA+ cells in %, median (IQR) | 26.5 (11.9–33.9) | 17.8 (5.8–26.2) | 1.03 (0.95–1.12) | 0.474 |
| CD8+ cell count/µl, median (IQR) | 603 (476–1141) | 340 (267–758) | 1.00 (1.00–1.00) | 0.614 |
| CD4/CD8 ratio, median (IQR) | 0.76 (0.33–1.15) | 0.96 (0.42–1.16) | 0.67 (0.08–4.59) | 0.679 |
| B cell count/µl, median (IQR) | 358 (145–454) | 380 (129–592) | 0.999 (1.00–1.00) | 0.584 |
| Memory B cells in %, median (IQR) | 10.7 (6.65–15.43) | 5.9 (4.3–14.55) | 1.10 (0.89–1.13) | 0.866 |
| IgG level in mg/dl, median (IQR) | 913 (739–1133) | 843 (557–1200) | 1.00 (1.00–1.00) | 0.569 |
| IgA level in mg/dl, median (IQR) | 115 (55–251) | 88 (56–161) | 1.01 (0.99–1.02) | 0.323 |
| IgM level in mg/dl, median (IQR) | 72 (45–123) | 97 (68–124) | 1.00 (0.98–1.00) | 0.459 |
| NT titer pretransplant patient, median (IQR) | 90 (60.3–280) | 135 (40–640) | 1.00 (0.99–1.00) | 0.518 |
| NT titer pretransplant donor, median (IQR) | 160 (67–190) | 160 (40–160) | 1.00 (0.99–1.00) | 0.380 |
| NT titer baseline patient, median (IQR) | 80.5 (19.5–129.5) | 40 (10–60) | 1.00 (0.99–1.02) | 0.192 |
AML acute myeloid leukemia, CD4+CD45RO+ cells memory CD4+ cells, CD4+CD45RA+ cells naive CD4+ cells, EBMT European Group for Blood and Marrow Transplantation, GvHD graft-versus-host disease, NT neutralization titer.
aAntibody response was defined by an NT titer of ≥10 and at least a twofold increase of titer from baseline (or titer above the highest level of measurement).
bT cell reconstitution = normal CD4+ and CD8+ cell counts.